New to Meducation?
Sign up
Already signed up? Log In

Category

Preview
2
40

Risk of GI bleeding associated with oral anticoagulants

Determining the real world safety of dabigatran or rivaroxaban compared with warfarin in terms of GI bleeding.  
bmj.com
almost 5 years ago
Preview
0
17

Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study

Objective To determine the real world risk of gastrointestinal bleeding associated with the use of the novel oral anticoagulants dabigatran and rivaroxaban compared with warfarin.  
feeds.bmj.com
almost 5 years ago
Preview
0
13

Safety of new oral anticoagulants

Two linked papers (doi:10.1136/bmj.h1857, doi:10.1136/bmj.h1585) report additional evidence on the risks of gastrointestinal bleeding among patients taking the novel oral anticoagulants dabigatran and rivaroxaban.1 2 From a database of more than 100 million US adults, Abraham and colleagues identified almost 220 000 new users of dabigatran, rivaroxaban, or warfarin between November 2010 and September 2013.1 In their comparison of propensity score matched patients, the risk of gastrointestinal bleeding increased significantly with age for both new oral anticoagulants, relative to warfarin. By age 75, the risk of gastrointestinal bleeding associated with rivaroxaban exceeded that with warfarin, for patients with or without atrial fibrillation. Among patients taking dabigatran, the association between older age and higher risk was confined to those with atrial fibrillation, although the data included very few patients without atrial fibrillation taking this drug.  
feeds.bmj.com
almost 5 years ago
Preview
0
15

Safety of new oral anticoagulants

Two linked papers (doi:10.1136/bmj.h1857, doi:10.1136/bmj.h1585) report additional evidence on the risks of gastrointestinal bleeding among patients taking the novel oral anticoagulants dabigatran and rivaroxaban.1 2 From a database of more than 100 million US adults, Abraham and colleagues identified almost 220 000 new users of dabigatran, rivaroxaban, or warfarin between November 2010 and September 2013.1 In their comparison of propensity score matched patients, the risk of gastrointestinal bleeding increased significantly with age for both new oral anticoagulants, relative to warfarin. By age 75, the risk of gastrointestinal bleeding associated with rivaroxaban exceeded that with warfarin, for patients with or without atrial fibrillation. Among patients taking dabigatran, the association between older age and higher risk was confined to those with atrial fibrillation, although the data included very few patients without atrial fibrillation taking this drug.  
feeds.bmj.com
almost 5 years ago
Www.bmj
0
24

Safety of new oral anticoagulants

Two linked papers (doi:10.1136/bmj.h1857, doi:10.1136/bmj.h1585) report additional evidence on the risks of gastrointestinal bleeding among patients taking the novel oral anticoagulants dabigatran and rivaroxaban.1 2 From a database of more than 100 million US adults, Abraham and colleagues identified almost 220 000 new users of dabigatran, rivaroxaban, or warfarin between November 2010 and September 2013.1 In their comparison of propensity score matched patients, the risk of gastrointestinal bleeding increased significantly with age for both new oral anticoagulants, relative to warfarin. By age 75, the risk of gastrointestinal bleeding associated with rivaroxaban exceeded that with warfarin, for patients with or without atrial fibrillation. Among patients taking dabigatran, the association between older age and higher risk was confined to those with atrial fibrillation, although the data included very few patients without atrial fibrillation taking this drug.  
feeds.bmj.com
almost 5 years ago
Www.bmj
0
6

Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study

Objectives To determine the real world safety of dabigatran or rivaroxaban compared with warfarin in terms of gastrointestinal bleeding.  
feeds.bmj.com
almost 5 years ago
Www.bmj
0
14

Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study

Objective To determine the real world risk of gastrointestinal bleeding associated with the use of the novel oral anticoagulants dabigatran and rivaroxaban compared with warfarin.  
feeds.bmj.com
almost 5 years ago
Preview
0
0

Safety of new oral anticoagulants

Two linked papers (doi:10.1136/bmj.h1857, doi:10.1136/bmj.h1585) report additional evidence on the risks of gastrointestinal bleeding among patients taking the novel oral anticoagulants dabigatran and rivaroxaban.1 2 From a database of more than 100 million US adults, Abraham and colleagues identified almost 220 000 new users of dabigatran, rivaroxaban, or warfarin between November 2010 and September 2013.1 In their comparison of propensity score matched patients, the risk of gastrointestinal bleeding increased significantly with age for both new oral anticoagulants, relative to warfarin. By age 75, the risk of gastrointestinal bleeding associated with rivaroxaban exceeded that with warfarin, for patients with or without atrial fibrillation. Among patients taking dabigatran, the association between older age and higher risk was confined to those with atrial fibrillation, although the data included very few patients without atrial fibrillation taking this drug.  
feeds.bmj.com
almost 5 years ago
Preview
0
4

Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study

Objectives To determine the real world safety of dabigatran or rivaroxaban compared with warfarin in terms of gastrointestinal bleeding.  
feeds.bmj.com
almost 5 years ago
Preview
0
1

Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study

Objectives To determine the real world safety of dabigatran or rivaroxaban compared with warfarin in terms of gastrointestinal bleeding.  
feeds.bmj.com
almost 5 years ago
Www.bmj
0
6

Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study

Objective To determine the real world risk of gastrointestinal bleeding associated with the use of the novel oral anticoagulants dabigatran and rivaroxaban compared with warfarin.  
feeds.bmj.com
almost 5 years ago
D2c071a5552599c7f6359e89638fd360b93a6e833876766676945077
1
145

The story of the discovery of heparin and warfarin

Douglas Wardrop and David Keeling Oxford Haemophilia and Thrombosis Centre, Oxford Radcliffe Hospitals, Oxford, UK  
Nicole Chalmers
almost 5 years ago
Preview
1
13

Warfarin Side Effects in Detail - Drugs.com

Learn about the potential side effects of warfarin. Includes common and rare side effects information for consumers and healthcare professionals.  
drugs.com
almost 5 years ago
Preview
0
1

A man with rust coloured urine and normocytic anaemia

A 65 year old man presented to the emergency department with a 10 day history of dark urine, general malaise, and progressive shortness of breath. He had a history of rheumatic heart disease and had been on warfarin since he had a metallic mitral valve replacement in 1984. He was a retired teacher, drank a minimal amount of alcohol, and was a non-smoker. He had no family history of cancer.  
feeds.bmj.com
almost 5 years ago
Www.bmj
0
0

A man with rust coloured urine and normocytic anaemia

A 65 year old man presented to the emergency department with a 10 day history of dark urine, general malaise, and progressive shortness of breath. He had a history of rheumatic heart disease and had been on warfarin since he had a metallic mitral valve replacement in 1984. He was a retired teacher, drank a minimal amount of alcohol, and was a non-smoker. He had no family history of cancer.  
feeds.bmj.com
almost 5 years ago
Www.bmj
0
6

Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study

Objective To determine the real world risk of gastrointestinal bleeding associated with the use of the novel oral anticoagulants dabigatran and rivaroxaban compared with warfarin.  
feeds.bmj.com
almost 5 years ago
Preview
0
1

Safety of new oral anticoagulants

Two linked papers (doi:10.1136/bmj.h1857, doi:10.1136/bmj.h1585) report additional evidence on the risks of gastrointestinal bleeding among patients taking the novel oral anticoagulants dabigatran and rivaroxaban.1 2 From a database of more than 100 million US adults, Abraham and colleagues identified almost 220 000 new users of dabigatran, rivaroxaban, or warfarin between November 2010 and September 2013.1 In their comparison of propensity score matched patients, the risk of gastrointestinal bleeding increased significantly with age for both new oral anticoagulants, relative to warfarin. By age 75, the risk of gastrointestinal bleeding associated with rivaroxaban exceeded that with warfarin, for patients with or without atrial fibrillation. Among patients taking dabigatran, the association between older age and higher risk was confined to those with atrial fibrillation, although the data included very few patients without atrial fibrillation taking this drug.  
feeds.bmj.com
almost 5 years ago
Preview
0
0

A man with rust coloured urine and normocytic anaemia

A 65 year old man presented to the emergency department with a 10 day history of dark urine, general malaise, and progressive shortness of breath. He had a history of rheumatic heart disease and had been on warfarin since he had a metallic mitral valve replacement in 1984. He was a retired teacher, drank a minimal amount of alcohol, and was a non-smoker. He had no family history of cancer.  
feeds.bmj.com
almost 5 years ago
Preview
0
15

A man with rust coloured urine and normocytic anaemia

A 65 year old man presented to the emergency department with a 10 day history of dark urine, general malaise, and progressive shortness of breath. He had a history of rheumatic heart disease and had been on warfarin since he had a metallic mitral valve replacement in 1984. He was a retired teacher, drank a minimal amount of alcohol, and was a non-smoker. He had no family history of cancer.  
feeds.bmj.com
almost 5 years ago